Drug Discount Monitor: Protect 340B, Cardiologist Asks Congress at Hearing on Drug Prices | 340B Matters
15652
post-template-default,single,single-post,postid-15652,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-9.1.3,wpb-js-composer js-comp-ver-4.11.1,vc_responsive

28 Apr Drug Discount Monitor: Protect 340B, Cardiologist Asks Congress at Hearing on Drug Prices

The chief clinical officer of one of Indiana’s largest safety-net hospitals implored Congress to protect the 340B drug discount program in light of “hyperinflation in pharmaceutical pricing.”

“I understand that some are calling for significant restructuring of the 340B program,” said cardiologist Dr. Richard Fogel of St. Vincent health system in written testimony submitted for an April 27 hearing by the Senate Special Committee on Aging. “As pharmaceutical companies are increasing prices at an alarming rate, I can’t think of a worse time to be thinking of cutting a program designed to make drugs more affordable for those at the lower end of the income spectrum.”

Read more.

 

 

Want To Stay Up-To-Date On The Latest 340B News?